BillionToOne, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Oguzhan Atay
- Full Time Employees
- 713
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 1035 O’Brien Drive Menlo Park CA United States of America 94025
- IPO Date
- Nov 6, 2025
- CIK
- 0002070849
- Website
- billiontoone.com
- Similar Companies
- Business
- BillionToOne, Inc. (Nasdaq: BLLN) develops and commercializes precision molecular diagnostics using its proprietary Quantitative Counting Templates (QCT) platform, which enables single-molecule DNA counting for prenatal screening and oncology applications; primary products include UNITY Screen and UNITY Complete, non-invasive prenatal tests (NIPT) assessing fetal risks for aneuploidies, recessive conditions, and fetal antigens from a single maternal blood draw at 9+ weeks gestation; Northstar Select, a liquid biopsy test for therapy selection via detection of tumor mutations including deletions, insertions, and point mutations; and Northstar Response, a complementary liquid biopsy for real-time cancer burden monitoring through methylation assessment. The company operates primarily in the United States, targeting obstetricians, gynecologists, oncologists, and healthcare networks with broad payer coverage; it was founded in 2016 and maintains headquarters in Menlo Park, California. Recent developments encompass a $314 million upsized initial public offering completed in November 2025, with shares trading under BLLN; a $130 million oversubscribed Series D funding round in June 2024 achieving over $1 billion valuation; expanded Medicare access via MolDx approval for Northstar Select in April 2025; launch of a 14-gene UNITY Fetal Risk Screen in May 2025; surpassing 500 employees and one million UNITY tests by November 2024 and March 2025, respectively; and a global collaboration with Johnson & Johnson announced in December 2023 for UNITY Fetal Antigen in a Phase 3 trial of nipocalimab for hemolytic disease of the fetus and newborn.
Company News
Billiontoone (NASDAQ:BLLN) CEO Sells $516,184.50 in Stock
BillionToOne to Report Third Quarter 2026 Financial Results on November 4, 2026
BillionToOne: A Molecular Diagnostics Stock With Strong Quality And GARP Credentials
BillionToOne's Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds
Billiontoone (NASDAQ:BLLN) Shares Down 4.6% After Insider Selling
Medicare Lab Fee Changes Impact BillionToOne, CareDx Differently
BillionToOne SVP Sells 1,416 Shares
BillionToOne CEO Liquidates Entire Directly-Held Stake in the Company for $3 Million
BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin
BillionToOne's Co-Founder Sells 10,000 Shares for $1 Million
/C O R R E C T I O N -- BillionToOne/
Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions
Billiontoone, Inc. (NASDAQ:BLLN) Receives $126.71 Average PT from Brokerages
BillionToOne: A Softer Quarter After Heightened Expectations
BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to Say
Billiontoone Q2 Earnings Call Highlights
BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar
BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026